Non-nutritive Sweeteners in Inflammatory Bowel Disease
Part of paid clinical trials in Chagrin Falls, Ohio.
- Sponsor
- University Hospitals Cleveland Medical Center
- Study ID
- NCT07769437
- Status
- Recruiting
Conditions
- Crohn Disease (CD)
- Inflamatory Bowel Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Accepted
Interventions
- Sucralose (non-nutritive sweetener) — OTHERParticipants will consume 2 sachets/day during the exposure period resulting in the following daily dose: sucralose 2.5mg/kg. This dose is below the acceptable daily intakes (ADI) of 5mg/kg.
Study Details
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with IBD, compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions).
Key Dates
- First listed
- Aug 18, 2026
- Start date
- Feb 3, 2025
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Crohn's participantsCrohn's participants will consume artificial sweetener: sucralose
- Experimental: Healthy ControlsHealthy control participants will consume artificial sweetener: sucralose
Primary Outcome Measure
Change in fecal microbiome measured by metagenome analysis [ Time Frame: Baseline, three weeks pre-intervention, and three weeks after intervention ]
Central Contacts
- Abigail Raffner, RD PhD216-327-6003
- Sargun Singh, M.B.B.S.216-333-6085
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UH Minoff Health Center | Chagrin Falls | Ohio | 44122 | Abigail Basson, RD PhD Jeffry Katz, MD (SUB_INVESTIGATOR) |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Abigail Basson, RD PhD Vu Nguyen, MD (SUB_INVESTIGATOR) Jeffry Katz, MD (SUB_INVESTIGATOR) |
| UH Westlake Health Center | Westlake | Ohio | 44145 | Abigail Basson, RD PhD Vu Nguyen, MD (SUB_INVESTIGATOR) |
Find similar trials in Chagrin Falls, OH
Related Studies
- Evaluation of the SMART IBD App in Pediatric IBDRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- Moving Beyond Inflammation as a Therapeutic Target for Crohn's DiseasePHASE2 · Recruiting · Washington University School of Medicine · Beverly Hills, California
- Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative ColitisPHASE4 · Not Yet Recruiting · Rubix LS · Lawrence, Massachusetts
- HB-adMSCs for the Treatment of Crohn's DiseasePHASE2 · Recruiting · Hope Biosciences Research Foundation · Sugar Land, Texas